Double depression refers to major depressive disorder (MDD)
superimposed on dysthymia (Keller & Shapiro, 1982) , a chronic, lowgrade depressive disorder. About three quarters of patients with dysthymia have or will experience a major depressive episode and, thus, suffer from double depression (Hellerstein & Eipper, 2013) . To date, associations of double depression with CVD risk markers or outcomes have not been examined. Nonetheless, double depression may be a stronger predictor of CVD due to its longer duration and higher recurrence rate than MDD alone and its greater symptom severity than dysthymia alone (Keller, Hirschfeld, & Hanks, 1997) .
Because no studies have examined atypical or double depression as predictors of new-onset CVD, our primary aim was to address these key gaps. Our secondary aim was to evaluate whether these relationships are independent of anxiety disorders. As anxiety disorders are highly comorbid with depressive disorders (Kessler et al., 2003) and also predict incident CVD (Roest, Martens, de Jonge, & Denollet, 2010) , it is important to adjust for them to isolate depression effects. We examined Wave 1 (2001) (2002) and Wave 2 (2004 Wave 2 ( -2005 data from a large, nationally representative sample of U.S. adults from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
MATERIALS AND METHODS

Study design and sample
NESARC is a prospective cohort study designed to determine the prevalence of alcohol use disorders and associated disabilities in the U.S. civilian noninstitutionalized population ≥18 years. Descriptions of study methods are provided elsewhere (Grant et al., 2005 (Grant et al., , 2009 Hasin & Grant, 2015) . NESARC received ethical approval from the U.S. Census Bureau and the U.S. Office of Management and Budget. At Wave 1, 43,093 respondents (81.0% response rate) completed computer-assisted home interviews assessing substance use disorders, psychiatric disorders, and medical conditions. Three years later (mean = 36.6 months) at Wave 2, 34,653 of the eligible Wave 1 respondents (86.7% response rate) completed a second home interview. A total of 3,134 Wave 1 respondents were not eligible for Wave 2 due to being deceased, deported, mentally or physically impaired, or on active duty in the armed forces. Respondents who participated in Waves 1 and 2, versus Wave 1 only, were younger (46.0 vs. 48.2 years) and more likely to be female (58.0 vs. 53.2%), to be non-Hispanic White (58.2 vs. 51.3%), to have a high school education or more (83.4 vs. 75.1%), and to have a lifetime depressive disorder (17.3 vs. 13.3%; all Ps < .001).
We applied three exclusion criteria to the Wave 2 sample. Respondents were excluded if: (1) CVD status at Wave 1 was positive (n = 1,742) or missing (n = 1,719), (2) CVD status at Wave 2 was missing (n = 1,065), or (3) CVD risk factors at Wave 1 were missing (n = 1,401). Characteristics of our final sample of 28,726 adults are shown in Table 1 .
Measures and procedures
Lifetime depressive disorder subtypes
Lifetime dysthymic disorder and MDD were determined by the Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV TA B L E 1 
Anxiety disorders
Lifetime anxiety disorder, % 10.5
Note: Continuous variables are presented as mean (standard deviation), and categorical variables are presented as percentage. Lifetime anxiety disorder consists of panic disorder, agoraphobia, generalized anxiety disorder, and social phobia.
(AUDADIS-IV), a fully structured diagnostic interview administered by lay interviewers assessing mental disorders using DSM-IV criteria (Ruan et al., 2008) . NESARC personnel coded diagnostic variables for the past year and prior to the past year. We used the NESARC variables that excluded illness-induced and substance-induced disorders and ruled out bereavement (Grant et al., 2005) . The AUDADIS-IV has demonstrated good test-retest reliability for depressive disorders (Grant et al., 2003) and generally good agreement with clinician evaluations (Hasin & Grant, 2015) .
From the NESARC variables, we computed two variables. Our first variable, atypical depression, had four levels: no depressive disorder, dysthymic disorder only, nonatypical MDD, and atypical MDD. First, we classified respondents into no depressive disorder history (never met criteria), lifetime dysthymic disorder only (past year or prior), and lifetime MDD (past year or prior) groups. Those who met criteria for both lifetime dysthymic disorder and MDD were placed into the MDD group. Then, we further classified respondents with lifetime MDD. The atypical MDD group consisted of respondents with both hyperphagia and hypersomnia. We coded individuals as having hyperphagia if they answered "yes" to either of the following AUDADIS-IV questions:
"During that time when your mood was at its lowest/you enjoyed or cared the least about things, did you gain at least 2 pounds a week for several weeks or at least 10 pounds altogether within a month (other than when you were growing or pregnant)?" or "During that time…, did you find that you wanted to eat a lot more than usual for no special reason, most days for at least 2 weeks?" We coded respondents as having hypersomnia if they answered "yes" to the AUDADIS-IV question, "During that time…, did you sleep more than usual nearly every day for at least 2 weeks?" While other criteria for atypical MDD exist (APA, 2013), using only the reversed somatic-vegetative symptoms is a valid approach (Benazzi, 2002) and has been utilized in past studies (Blanco et al., 2012; Chou & Yu, 2013; Horwath, Johnson, Weissman, & Hornig, 1992; Matza, Revicki, Davidson, & Stewart, 2003 
Incident CVD
Using data from the NESARC Medical Conditions and Practices questionnaire administered at Wave 2, we computed an incident CVD variable comprised of new-onset arteriosclerosis, angina, or myocardial infarction (MI) based on self-reported physician diagnoses. In Part A, respondents were asked, "In the last 12 months, did you have: (1) hardening of the arteries or arteriosclerosis? (2) chest pain or angina pectoris? (3) a heart attack or MI?" If the answer to Part A was "yes," in Part B respondents were asked, "Did a doctor or other health professional tell you that you had (name of condition)?" We coded respondents as positive for incident CVD if they answered "yes" to Parts A and B for at least one CVD question, and we coded respondents as negative if they answered "no" to all three Part A questions. Those who were coded as "unknown" for Part A or B for one or more questions and who did not answer "yes" to Part A and B for at least one question were coded as missing for incident CVD and were excluded. To compute a corresponding baseline CVD variable, we applied the same coding scheme to the identical Wave 1 CVD questions. Because our focus is predicting new-onset CVD, we included only respondents coded negative for baseline CVD.
Potential confounders
The following variables-which could operate as potential confounders of depression-CVD associations (Luger, Suls, & Vander Weg, 2014; Luppino et al., 2010; Nouwen et al., 2010) -were included as control variables in the models: age (years), sex (0 = male, 1 = female), race/ethnicity, education level, hypertension, hypercholesterolemia, diabetes, tobacco use, body mass index (BMI), and lifetime anxiety disorder. These variables were based on self-reported data from Wave 1 except hypercholesterolemia and diabetes, which were assessed only at Wave 2. We recoded race/ethnicity into a four-level variable (0 = non-Hispanic White, 1 = non-Hispanic Black, 2 = Hispanic or Latino, 3 = Other). Next, we created three dummy-coded variables using non-Hispanic White as the reference category. Education level was assessed by the question, "Highest grade or year of school completed?" From these data, we computed a 4-level variable (0 = less than high school, 1 = high school or equivalent, 2 = some college or Associate's degree, 3 = Bachelor's degree or higher). Three dummy-coded variables using less than high school as the reference category were then created.
We coded respondents as positive for hypertension, hypercholesterolemia, and diabetes, respectively, if they answered "yes" to "In the past 12 months, have you had: (1) high blood pressure or hypertension? (2) high cholesterol? (3) diabetes or sugar diabetes?" and "yes" to "Did a doctor or other health professional tell you that you had (name of condition)?" We coded respondents as negative for each condition if they answered "no" to the first question. Those coded by NESARC personnel as "unknown" for either question were coded as missing for that condition and were excluded. We recoded NESARC's tobacco use variable (current user, former user, lifetime nonuser) into a dichotomous variable (0 = current nonuser, 1 = current user). BMI (kg/m 2 ) was computed from self-reported height and weight.
We computed a lifetime anxiety disorder variable using AUDADIS-IV data collected at Wave 1. Respondents who were coded by NESARC personnel as meeting diagnostic criteria for panic disorder, agoraphobia, generalized anxiety disorder, or social phobia in the past year or prior (illness-and substance-induced disorders excluded) were coded as positive for lifetime anxiety disorder. Those not meeting criteria for any of these disorders were coded as negative.
Data analysis
We ran three sets of logistic regression analyses-demographics adjusted, CVD risk factor adjusted, and anxiety disorder adjustedexamining the atypical depression variable as a predictor of incident CVD. For each set, we ran three models, each of which used a different reference category (1 = no depressive disorder, 2 = dysthymic disorder only, 3 = nonatypical MDD). Control variables in the demographics adjusted models were age, sex, race/ethnicity, and education level. The CVD risk factor adjusted models were further adjusted for hypertension, hypercholesterolemia, diabetes, tobacco use, and BMI. The anxiety disorder adjusted models additionally included lifetime anxiety disorder. Finally, we ran an identical series of logistic regression analyses for the double depression variable. All selected control variables were significantly associated with the atypical depression and double depression variables.
Analyses were conducted with SAS statistical software, version 9.3.
Models were weighted to account for oversampling, probabilities of selection, and nonresponse. Weighted analyses provide estimates for U.S. civilian noninstitutionalized population based on the 2000 Decennial Census (Hasin & Grant, 2015) .
RESULTS
Depressive disorder subtypes and incident CVD
The lifetime prevalence was 3.4% (964 cases) for atypical MDD and 3.1% (833 cases) for double depression. The degree of overlap between these two subtypes was modest, as the phi coefficient (r ) was 0.22, 
TA B L E 2 Logistic regression models examining atypical depression as a predictor of incident cardiovascular disease
Atypical depression as a predictor of incident CVD
Demographic adjusted logistic regression models (Table 2) revealed that respondents with atypical MDD had over twice the odds of incident CVD than those with no depressive disorder (P < .001).
Although adults with dysthymic disorder only (37% greater odds; P = .043) or nonatypical MDD (51% greater odds; P < .001) were more likely to develop CVD than nondepressed adults, the magnitude of these associations was less than half of that for atypical MDD. These models also indicated that the odds of CVD in the atypical MDD group were greater than in the dysthymic disorder only (OR = 1.61, 95%
CI: 1.08-2.39, P = .019) and nonatypical MDD (OR = 1.46, 95% CI:
1.11-1.91, P = .006) groups.
CVD risk factor adjusted and anxiety disorder adjusted models (Table 2 ) yielded a similar pattern of results, although associations were attenuated and some fell short of significance. Respondents with atypical MDD remained at the highest risk of incident CVD, with a 78% (P < .001) and 56% (P = .001) greater odds than nondepressed adults. However, comparisons of the atypical MDD group with the dysthymic disorder only group (CVD risk factor adjusted OR = 1.46, 95% CI: 0.97-2.18, P = .068; anxiety disorder adjusted OR = 1.39, 95% CI: 0.92-2.09, P = .12) and the nonatypical MDD group (CVD risk factor adjusted OR = 1.25, 95% CI: 0.94-1.65, P = .13; anxiety disorder adjusted OR = 1.22, 95% CI: 0.92-1.61, P = .18) were no longer significant. In the CVD risk factor adjusted and anxiety disorder adjusted models, nonatypical MDD also continued to predict incident CVD (P < .001 and .004), whereas dysthymic disorder did not (P = .21 and .48).
Double depression as a predictor of incident CVD
Demographics adjusted models (Table 3) indicated that respondents those with double depression had more than twice the odds of incident CVD than nondepressed adults (P < .001). Dysthymic disorder only (36% greater odds; P = .044) and MDD only (49% greater odds; P < .001) also predicted incident CVD but these relationships were not as strong as that for double depression. The double depression group also had higher odds of incident CVD than the dysthymic disorder only (OR = 1.59, 95% CI: 1.16-2.19, P = .004) and MDD only (OR = 1.46, 95% CI: 1.20-1.77, P < .001) groups.
Although associations were again attenuated, the pattern of results was similar in the CVD risk factor adjusted and anxiety disorder adjusted models (Table 3) . Adults with double depression remained at the highest odds of incident CVD. This group had a 95% (P < .001) and 65% (P < .001) greater odds than those in the no depressive disorder group, and comparisons with the dysthymic disorder only group (CVD risk factor adjusted OR = 1.61, 95% CI: 1.16-2.21, P = .004; anxiety disorder adjusted OR = 1.47, 95% CI: 1.07-2.02, P = .018) and the MDD only group (CVD risk factor adjusted OR = 1.42, 95% CI:
1.16-1.73, P = .001; anxiety disorder adjusted OR = 1.31, 95% CI:
1.08-1.59, P = .006) continued to be significant. In the CVD risk factor adjusted and anxiety disorder adjusted models, MDD only (P < .001
and P = .016)-but not dysthymic disorder only (P = .22 and .48)-remained a predictor of incident CVD.
DISCUSSION
Our examination of the NESARC data indicates that atypical MDD and double depression are two depressive disorder subtypes that may be particularly strong predictors of new-onset CVD. With respect to atypical MDD, U.S. adults with a lifetime history of this subtype had a higher odds of incident CVD than those with no depression history, dysthymic disorder only, or nonatypical MDD in demographics adjusted models.
Although a similar pattern of results was observed in CVD risk factor adjusted models, some comparisons fell short of significance. Concerning double depression, U.S. adults with a lifetime history of subtype had a higher odds of incident CVD than those with no depression history, dysthymic disorder only, or MDD only in both demographics and CVD risk factor adjusted models. Further adjustment for lifetime anxiety disorder attenuated associations but did not alter the pattern of results for either subtype. The modest degree of overlap between atypical MDD and double depression suggests that their associations with incident CVD likely reflect separate relationships; however, the 228 cases with both subtypes did contribute to both relationships.
Collectively, our findings indicate that adults with atypical MDD or double depression may be subgroups of the depressed population at greatest risk of developing CVD and, thus, may be driving the overall depression-CVD relationship.
Our study addresses a key gap in the literature-that is, the absence of prospective studies examining atypical depression or double depression as predictors of incident CVD. Our findings do conflict with three prior studies that observed no difference in prevalent CVD between depressed adults with versus without atypical features (Niranjan et al., 2012) and no associations between atypical MDD symptoms and prevalent CVD (Fraguas et al., 2007; Vogelzangs et al., 2010) . However, due to their cross-sectional design, reverse causality may have obscured depression subtype differences (Spijkerman et al., 2005) . To our knowledge, there are no previous studies that have examined associations between double depression and CVD risk markers or outcomes. Although one other prospective analysis of the NESARC data reported the association of lifetime MDD with CVD, the focus of that analysis was the bipolar disorder-incident CVD relationship, and depressive disorder subtypes were not examined (Goldstein, Schaffer, Wang, & Blanco, 2015) .
There are multiple candidate mechanisms that could explain why atypical MDD may be a stronger predictor of incident CVD. Evidence suggests that conventional CVD risk factors are elevated in adults with atypical versus nonatypical depression (Chou & Yu, 2013; Cizza et al., 2012; Glaus et al., 2013; Lamers et al., 2013; Levitan et al., 2012; Niranjan et al., 2012; Takeuchi et al., 2013; van Reedt Dortland et al., 2010) . Moreover, atypical MDD has been found to predict incident obesity and increases in BMI, waist circumference, and fat mass over time (Lasserre et al., 2014) . In our models adjusting for Wave 1 CVD risk factors, associations were attenuated. However, because depressive disorders and CVD risk factors were assessed at the same point, the NESARC data cannot be used to determine whether the CVD risk factors were operating as confounders or mediators. Given that our objective was to provide unbiased estimates of the associations between depressive disorder subtypes and incident CVD, we chose to treat the CVD risk factors as potential confounders to be conservative. In addition to conventional CVD risk factors, other mechanisms may also be at work. Another candidate mechanism, which was not assessed in NESARC, is greater systemic inflammation. Adults with atypical depression, versus those with nonatypical depression, have been found to have higher circulating levels of inflammatory markers predictive of CVD, such as C-reactive protein and interleukin-6 (Hickman et al., 2014; Lamers et al., 2013; Rudolf, et al., 2014) . Two other candidate mechanisms are poor diet quality (Rahe et al., 2015) and low physical activity (Glaus et al., 2013; Matza et al., 2003) . In addition to these biological and behavioral pathways, adults with atypical MDD may have greater lifetime exposure to depression, given that it is characterized by earlier age of onset, more severe symptoms, and a greater number of episodes (Blanco et al., 2012; Matza et al., 2003; Novick et al., 2005) .
Less is known about the correlates of double depression that could be operating as underlying mechanisms. Like atypical depression, associations were attenuated after adjustment for conventional CVD risk factors, suggesting that they may partially explain the elevated CVD risk of this group. It is also plausible that double depression is a stronger predictor of incident CVD on account of its longer duration and higher recurrence rate than MDD alone and its greater symptom severity than dysthymia alone (Keller et al., 1997) , resulting in greater lifetime exposure to depression and the associated atherogenic biological and behavioral changes (Grippo & Johnson, 2002; Joynt, Whellan, & O'Connor, 2003) . In addition, a smaller study found that patients with double depression reported greater hopelessness than patients with MDD or dysthymia (Joiner, Cook, Hersen, & Gordon, 2007) . Hopelessness has been linked with greater subclinical atherosclerosis (Whipple et al., 2009 ) and an increased risk of CVD events (Everson et al., 1996) , independent of depressive symptoms. Clearly, there is a need for studies examining associations of double depression with CVD outcomes and candidate mechanisms.
The present study has key strengths, including the longitudinal design, large nationally representative sample, and structured interview assessments of psychiatric disorders. NESARC is the largest and most comprehensive psychiatric epidemiologic survey conducted in the United States (Hasin & Grant, 2015) , and its prospective data allowed us to draw strong inferences regarding directionality. Our study also has limitations that should be considered. First, epidemiologic surveys often assess CVD by self-report of physician diagnoses.
Supporting this approach, agreement between self-reported and medical record-ascertained CVD has been found to be acceptable to good (Barr, Tonkin, Welborn, & Shaw, 2009; Bergmann, Byers, Freedman, & Mokdad, 1998; Heckbert et al., 2004; Lampe, Walker, Lennon, Whincup, & Ebrahim, 1999; Machon et al., 2013; Okura, Urban, Mahoney, Jacobsen, & Rodeheffer, 2004) . A recent study (Yasaitis, Berkman, & Chandra, 2015) diagnoses in the past 12 months only. This is less of a concern for arteriosclerosis and angina, as these are chronic conditions and not discrete events. Our composite incident CVD outcome also reduces the potential for misclassification, given that respondents who suffered nonfatal MIs between Waves 1 and 2, but prior to the past 12 months, may have also been diagnosed with one of the other CVD conditions during follow-up. Fourth, due to the limited temporal resolution of the diagnostic variables, our double depression definition did not take into account the order of onset or co-occurrence of dysthymic disorder and MDD. Future studies with diagnostic variables possessing greater temporal resolution are needed to examine the importance of these characteristics in predicting incident CVD. Fifth, although age ranged from 18 to 97 years in our sample, the mean age was only 45 years, and the follow-up period was only three years. Both of these factors likely contributed to the lower rate (3.9%) of incident CVD.
CONCLUSION
We report prospective evidence from a nationally representative sample indicating that U.S. adults with atypical MDD or double depression may be subgroups of the depressed population at particularly high risk of new-onset CVD who may be driving the depression-CVD relationship. With respect to research implications, our results suggest that clinical trials evaluating whether successful depression treatment reduces CVD risk should consider specifically recruiting patients with atypical MDD or double depression, as it is in these subgroups where most of the excess CVD risk seems to reside. Furthermore, our findings underscore the need to continue to test existing treatments (Fournier et al., 2013) 
